Ivermectin binds avidly to plasma proteins

No abstract is available for this paper.

• Publication year

  2004

• Venue

  European Journal of Clinical Pharmacology

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/BF00316107PMID 2095348
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The relative systemic availability of ivermectin after administration as capsule, tablet, and oral solution

  2004cited by this paper
• The chemotherapy of onchocerciasis X. An assessment of four single dose treatment regimes of MK-933 (ivermectin) in human onchocerciasis.

  1985cited by this paper

• COVID-19 and a Tale of Three Drugs: To Repurpose, or Not to Repurpose–That Was the Question

  2025cites this paper
• Ivermectin impact over gut microbiota diversity: A comprehensive and updated analysis from pre-clinical and clinical evaluations

  2025cites this paper
• Optimizing endectocide and ectocide compound evaluation in Anopheles malaria vectors

  2025influential citation
• Membrane Perturbations and Assay Interferences by Ivermectin Explain Its In Vitro SARS-CoV‑2 Antiviral Activities and Lack of Translatability

  2025cites this paper
• The Ameliorating Effect Of Co_Enzyme Q10 On Kidneys After Administration Of Ivermectin In Rabbits

  2024cites this paper
• Safety, pharmacokinetics, and potential neurological interactions of ivermectin, tafenoquine, and chloroquine in Rhesus macaques

  2024cites this paper
• Antiplasmodial and Insecticidal Activities of Third-Generation Ivermectin Hybrids

  2024cites this paper
• Strongyloides stercoralis infection in solid organ transplant recipients

  2024cites this paper
• Pharmacokinetics of ivermectin metabolites and their activity against Anopheles stephensi mosquitoes

  2023cites this paper
• A cellular and molecular biology-based update for ivermectin against COVID-19: is it effective or non-effective?

  2023cites this paper
• Nonspecific membrane bilayer perturbations by ivermectin underlie SARS-CoV-2 in vitro activity

  2023cites this paper
• Computational Prediction of the Interaction of Ivermectin with Fibrinogen

  2023cites this paper
• Ivermectin metabolites reduce Anopheles survival

  2023cites this paper
• Could the COVID-19-Driven Increased Use of Ivermectin Lead to Incidents of Imbalanced Gut Microbiota and Dysbiosis?

  2022influential citation
• Comprehensive review on repurposing of approved medicine in the management of COVID-19 infection

  2022cites this paper
• SARS-CoV-2 Spike Protein Induces Hemagglutination: Implications for COVID-19 Morbidities and Therapeutics and for Vaccine Adverse Effects

  2022cites this paper
• The investigation of the complex population-drug-drug interaction between ritonavir-boosted lopinavir and chloroquine or ivermectin using physiologically-based pharmacokinetic modeling

  2022cites this paper
• Repurposing Potential of the Antiparasitic Agent Ivermectin for the Treatment and/or Prophylaxis of COVID-19

  2022cites this paper
• Ivermectin-induced cell death of cervical cancer cells in vitro a consequence of precipitate formation in culture media.

  2022cites this paper
• Ivermectin: a mini-review

  2022cites this paper
• Remdesivir–ivermectin combination displays synergistic interaction with improved in vitro activity against SARS-CoV-2

  2022cites this paper
• Ivermectin and mortality in patients with COVID-19: A systematic review, meta-analysis, and meta-regression of randomized controlled trials

  2021cites this paper
• Tinjauan Biomedis Antiparasit Ivermectin Dalam Pengobatan COVID-19

  2021cites this paper
• The mechanisms of action of ivermectin against SARS-CoV-2—an extensive review

  2021cites this paper
• Current Use of Ivermectin in Dermatology, Tropical Medicine, and COVID-19: An Update on Pharmacology, Uses, Proven and Varied Proposed Mechanistic Action

  2021cites this paper
• Modeling of SARS-CoV-2 Treatment Effects for Informed Drug Repurposing

  2021cites this paper
• Metabolism and interactions of Ivermectin with human cytochrome P450 enzymes and drug transporters, possible adverse and toxic effects

  2021cites this paper
• Uso de ivermectina en pacientes con la COVID-19: Una revisión narrativa

  2021cites this paper
• RETRACTED ARTICLE: The mechanisms of action of Ivermectin against SARS-CoV-2: An evidence-based clinical review article

  2021cites this paper
• Differences in P-glycoprotein activity in human and rodent blood–brain barrier assessed by mechanistic modelling

  2021cites this paper
• Considerations for interactions of drugs used for the treatment of COVID-19 with anti-cancer treatments

  2020cites this paper
• Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action

  2020cites this paper
• Development of a Minimal Physiologically-Based Pharmacokinetic Model to Simulate Lung Exposure in Humans Following Oral Administration of Ivermectin for COVID-19 Drug Repurposing

  2020cites this paper
• Ivermectin for COVID-19 Treatment: Clinical Response at Quasi-Threshold Doses Via Hypothesized Alleviation of CD147-Mediated Vascular Occlusion

  2020cites this paper
• The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID‐19

  2020influential citation
• The Repurposing of Ivermectin for Malaria: A Prospective Pharmacokinetics-Based Virtual Clinical Trials Assessment of Dosing Regimen Options.

  2018cites this paper
• HISTOPATHOLOGICAL AND BIOCHEMICAL EFFECTS OF IVERMECTIN ON KIDNEY FUNCTIONS , LUNG AND THE AMELIORATIVE EFFECTS OF VITAMIN C IN RABBITS ( Lupus cuniculus ) Khawla

  2016cites this paper
• Physiologically based pharmacokinetic (PBPK) model of Ivermectin (IVM)

  2014influential citation
• Pharmacokinetic Interaction of Ivermectin and Triclabendazole Following Co-administration to Sheep

  2014cites this paper
• Ivermectin

  2012cites this paper
• Effects of Ivermectin on Blood-Feeding Phlebotomus papatasi, and the Promastigote Stage of Leishmania major

  2011cites this paper
• Unchanged triclabendazole kinetics after co-administration with ivermectin and methimazole: failure of its therapeutic activity against triclabendazole-resistant liver flukes

  2010cites this paper
• Agents Active against Parasites and Pneumocystis

  2010cites this paper
• Serum ivermectin levels after enteral and subcutaneous administration for Strongyloides hyperinfection: A case report

  2010cites this paper
• Comparative pharmacokinetics of some injectable preparations containing ivermectin in dogs.

  2010cites this paper
• Combined use of ivermectin and triclabendazole in sheep: in vitro and in vivo characterisation of their pharmacological interaction.

  2009cites this paper
• Case report: failure of subcutaneous ivermectin in treating Strongyloides hyperinfection.

  2008cites this paper
• Retinopathy associated with ivermectin toxicosis in two dogs.

  2008cites this paper
• The Pharmacokinetics and Interactions of Ivermectin in Humans—A Mini-review

  2008influential citation
• The Pharmacokinetics and Interactions of Ivermectin in Humans—A Mini-review

  2008cites this paper
• MACROCYCLIC LACTONES (Veterinary—Systemic)

  2006cites this paper
• Treatment of human disseminated strongyloidiasis with a parenteral veterinary formulation of ivermectin.

  2005cites this paper
• Parenteral administration of ivermectin in a patient with disseminated strongyloidiasis.

  2005cites this paper
• Biowaiver monographs for immediate release solid oral dosage forms: ranitidine hydrochloride.

  2005cites this paper
• Macrocyclic lactones: distribution in plasma lipoproteins of several animal species including humans.

  2004cites this paper
• [Ivermectin].

  2004cites this paper
• Ivermectin levels in human breastmilk

  2004cites this paper
• [Ivermectin, a broad spectrum antiparasitic drug].

  2002cites this paper
• Ivermectin in reindeer feces: determination by HPLC.

  1999cites this paper
• Cyclosporin A and trifluoperazine, two resistance-modulating agents, increase ivermectin neurotoxicity in mice.

  1999cites this paper
• Avermectins and milbemycins.

  1996cites this paper
• Ivermectin detection in serum of onchocerciasis patients: relationship to adverse reactions.

  1995cites this paper
• Protein binding and ivermectin estimations in patients with onchocerciasis

  1993cites this paper
• Concurrent parasitic infections in onchocerciasis and the occurrence of adverse reactions after ivermectin treatment.

  1993cites this paper
• Ivermectin levels in human breast milk

  1993cites this paper
• Adverse events following mass ivermectin therapy for onchocerciasis.

  1992cites this paper
• Retinopathy associated with ivermectin toxicosis in two dogs

  year unknowncites this paper
• Retinopathy associated with ivermectin toxicosis in two dogs

  year unknowncites this paper
• Retinopathy associated with ivermectin toxicosis in two dogs

  year unknowncites this paper
• Retinopathy associated with ivermectin toxicosis in two dogs

  year unknowncites this paper
• Retinopathy associated with ivermectin toxicosis in two dogs

  year unknowncites this paper
• Retinopathy associated with ivermectin toxicosis in two dogs

  year unknowncites this paper
• Retinopathy associated with ivermectin toxicosis in two dogs

  year unknowncites this paper
• Retinopathy associated with ivermectin toxicosis in two dogs

  year unknowncites this paper
• Retinopathy associated with ivermectin toxicosis in two dogs

  year unknowncites this paper
• Retinopathy associated with ivermectin toxicosis in two dogs

  year unknowncites this paper
• Retinopathy associated with ivermectin toxicosis in two dogs

  year unknowncites this paper
• Retinopathy associated with ivermectin toxicosis in two dogs

  year unknowncites this paper